Recently, upfront IL-6 blockade mitigated irAE symptoms in a murine model of experimental autoimmune encephalomyelitis while preserving antitumor activity after anti-CTLA-4 exposure (53). Here, IL6 is linked to experimental autoimmune encephalomyelitis.